标题
Personalized Targeted Therapy for Lung Cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 13, Issue 9, Pages 11471-11496
出版商
MDPI AG
发表日期
2012-09-14
DOI
10.3390/ijms130911471
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).
- (2017) M. J. Boyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
- (2017) L. Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).
- (2017) C. Sorlini et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer.
- (2017) W. Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
- (2017) A. Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
- (2017) Marina Chiara Garassino et al. JOURNAL OF CLINICAL ONCOLOGY
- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Treatment of Lung Cancer With Targeted Therapy
- (2012) Philip T. Cagle et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
- (2012) Gargi Ghosh et al. BMC CANCER
- A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
- (2012) Takashi Kobayashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
- (2012) Takenori Ogawa et al. CELL CYCLE
- High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
- (2012) Y. Lee et al. CLINICAL CANCER RESEARCH
- Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
- (2012) Fausto Petrelli et al. Clinical Lung Cancer
- Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
- (2012) A. Ballestrero et al. CURRENT CANCER DRUG TARGETS
- ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
- (2012) Giorgio Scagliotti et al. EUROPEAN JOURNAL OF CANCER
- Lung cancer in never smokers – A review
- (2012) Sébastien Couraud et al. EUROPEAN JOURNAL OF CANCER
- Emerging personalized oncology: sequencing and systems strategies
- (2012) William Cho et al. Future Oncology
- Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung Cancer
- (2012) Su-Jung Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
- (2012) Michele Milella et al. Journal of Thoracic Oncology
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer
- (2012) M. Catherine Pietanza et al. Journal of Thoracic Oncology
- The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis
- (2012) Simon Ekman et al. Journal of Thoracic Oncology
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Molecular pathology of lung cancer: key to personalized medicine
- (2012) Liang Cheng et al. MODERN PATHOLOGY
- Abstract C191: Preclinical investigation of the antitumor efficacy in lung cancer of Y15, a novel focal adhesion kinase inhibitor.
- (2012) G. K. Dy et al. MOLECULAR CANCER THERAPEUTICS
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of small molecule cancer drugs: Successes, challenges and opportunities
- (2012) Swen Hoelder et al. Molecular Oncology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
- (2011) C.P. Belani et al. CANCER TREATMENT REVIEWS
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma
- (2011) Ornella Belvedere et al. GENOMICS
- Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
- (2011) S. Matsuura et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Personalized medicine in lung cancer: what we need to know
- (2011) Tony S. K. Mok Nature Reviews Clinical Oncology
- Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
- (2011) Giulia M. Stella et al. RESPIRATORY MEDICINE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- (2010) Christian C. Lee et al. BIOCHEMICAL JOURNAL
- Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma
- (2010) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
- (2010) Yihua Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705
- (2010) Hiroshige Yoshioka et al. Journal of Thoracic Oncology
- A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
- (2010) Dong-Wan Kim et al. LUNG CANCER
- Head and Neck Squamous Cell Carcinoma: New Translational Therapies
- (2010) Anthony Prince et al. MOUNT SINAI JOURNAL OF MEDICINE
- The mutation spectrum revealed by paired genome sequences from a lung cancer patient
- (2010) William Lee et al. NATURE
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
- (2010) Filip Janku et al. Nature Reviews Clinical Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
- (2009) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
- (2009) Rafael Rosell et al. PLoS One
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
- (2008) K Tamura et al. BRITISH JOURNAL OF CANCER
- Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
- (2008) A. F. Gazdar et al. Cancer Prevention Research
- Advances in Breast Cancer: Pathways to Personalized Medicine
- (2008) O. I. Olopade et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction
- (2008) Andrew H. Ko et al. GASTROENTEROLOGY
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
- (2008) Kenji Sugio et al. LUNG CANCER
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story
- (2007) Lecia V. Sequist et al. Annual Review of Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More